## Andrey A Lysenko

## List of Publications by Year

 in descending orderSource: https:|/exaly.com/author-pdf/2504841/publications.pdf
Version: 2024-02-01


| 1 | Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Human Vaccines and Immunotherapeutics, 2017, 13, 613-620. | 3.3 | 92 |
| :---: | :---: | :---: | :---: |
| 2 | Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Research, 2013, 97, 245-254. | 4.1 | 35 |
| 3 | Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Research, 2013, 97, 318-328. | 4.1 | 35 |
| 4 | Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. PLoS ONE, 2018, 13, e0191574. | 2.5 | 23 |
| 5 | The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector. BMC Immunology, 2018, 19, 26. | 2.2 | 7 |
| 6 | Construction of recombinant adenoviral vector expressing genes of the conservative proteins M2 $\hat{a} € œ i o n ~ c h a n n e l a ̂ € \cdot a n d ~ n u c l e o p r o t e i n ~ o f ~ i n f l u e n z a ~ A ~ v i r u s . ~ M o l e c u l a r ~ G e n e t i c s, ~ M i c r o b i o l o g y ~ a n d ~$ Virology, 2014, 29, 69-76. | 0.3 | 2 |
| 7 | Human TRIM14 protects transgenic mice from influenza A viral infection without activation of other innate immunity pathways. Genes and Immunity, 2021, 22, 56-63. | 4.1 | 2 |

Protecting Mice from H7 Avian Influenza Virus by Immunisation with a Recombinant Adenovirus
8 Encoding Influenza A Virus Conserved Antigens. BIOpreparations Prevention Diagnosis Treatment, 0.5 2020, 20, 60-67.

A Study of the Immunogenicity and Protective Properties of Recombinant Influenza Vaccine. Molecular Genetics, Microbiology and Virology, 2020, 35, 159-167.

